

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/016,969	12/14/2001	Richard A. Pittner	0401-UTL-0	7314
28381	7590 06/22/2004	EXAMINER		
ARNOLD & PORTER LLP ATTN: IP DOCKETING DEPT.			LI, RUIXIANG	
555 TWELFTH STREET, N.W.			ART UNIT	PAPER NUMBER
WASHINGT	ON, DC 20004-1206		1646	
			DATE MAILED: 06/22/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. Applicant(s) 10/016,969 PITTNER ET AL. Interview Summary Examiner Art Unit 1646 Ruixiang Li All participants (applicant, applicant's representative, PTO personnel): (1) Ruixiang Li. (3)Mi K. Kim. (4) Richard Pittner. (2) Gary Kunz. Date of Interview: 15 June 2004. Type: a) ☐ Telephonic b) ☐ Video Conference c) Personal [copy given to: 1) applicant 2) applicant's representative e) No. Exhibit shown or demonstration conducted: d) Yes If Yes, brief description: . Claim(s) discussed: 1,8 and 33-54. Identification of prior art discussed: See Continuation Sheet. Agreement with respect to the claims f) \square was reached. g) \bowtie was not reached. h) \square N/A. Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet. (A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.) THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet. Zuixiang L. Examiner Note: You must sign this form unless it is an

U.S. Patent and Trademark Office PTOL-413 (Rev. 04-03)

Attachment to a signed Office action.

Examiner's signature, if required

Application No. 10/016,969

The Endocrine Society 75th Annual Meeting Prograpm & Abstract, page 180, Abstract 520B, 1993; Yoshinaga et al., Am. J. Physiol. 263:G695-701, 1992; Ueno et al., Gastroenterology, 117:1427-1432, 1999.

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The obviousness of the 103 (a) rejections set forth in the previous office action mailed on 03/03/2004 was discussed. Applicants submitted that it would have not been obvious to an artisan at the time the invention was made to use the PYY or a PYY agonist, e.g., PYY3-36, in the method of treating obesity and reducing food intake taught by Malaisse-Lagae et al. because PP and PYY have distinct pharmacologic properties. The Examiner maintained the rejections.